Mercury content (μg Hg/0.5 mL): http://www.cdc.gov/flu/protect/vaccine/vaccines.htm
Other ingredients in the flu shot: http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf
Vaccine-Associated Enhanced Respiratory Disease: Vaccination may make flu worse if exposed to a second strain; http://medicalxpress.com/news/2013-08-vaccination-flu-worse-exposed-strain.html
Study: seasonal flu vaccination increases risk of other lab-conf respiratory infections; http://cid.oxfordjournals.org/content/early/2012/03/13/cid.cis307.full.pdf+html
Annual Flu Vaccines Could Leave People Vulnerable to Novel Pandemics; Article about Study – http://www.ibtimes.com/annual-flu-vaccines-could-leave-people-vulnerable-novel-pandemics-study-371160
- The Full Prescribing information for Fluzon high dose
One must visit the publicly shared FDA documents on vaccine approvals where you will find, inside the “Summary Basis of Regulatory Action letter, and inside the following information about the vaccine ingredients:
Like the licensed trivalent influenza vaccines, Fluzone Quadrivalent is a sterile suspension prepared from influenza viruses propagated in embryonated chicken eggs. The virus is harvested from the allantoic fluid, inactivated with formaldehyde, concentrated, purified in a linear sucrose density gradient solution using a continuous flow centrifuge, and finally chemically disrupted using a non-ionic surfactant, Octylphenol Ethoxylate (Triton® X-100) to produce a “split virus”. This split virus is then further purified and suspended in sodium phosphate-buffered isotonic sodium chloride solution. The upstream manufacturing processing of Fluzone Quadrivalent is identical to that for Fluzone High-Dose, and differs only in the formulation of the final bulk to a lower concentration per mL in order to achieve a 15 μg HA per strain/dose at a volume of 0.5 mL. Data derived from 3 consecutive batches of final bulk product demonstrated validation of the Fluzone Quadrivalent formulation process.